SEC Form DFiling only, no announcement found
FibroBiologics, based in Houston, TX, reported $500,001 sold in a private offering of equity and options or warrants, with the first sale on September 15, 2026, in a Form D filed with the SEC on September 16, 2026. The filing says 1 investor has already invested.
Legal name on the filing: FibroBiologics, Inc.. Formerly FibroBiologics Inc..
| Amount sold | $500,001Basis: Form D total amount sold, as of the filing of September 16, 2026. Not the announced round size. |
|---|---|
| Total offering | $500,001The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire another security; Security to be acquired upon exercise of option, warrant or other right |
| Exemption claimed | Rule 506(b) |
| Date of first sale | September 15, 2026 |
| Investors already invested | 1 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Pharmaceuticals |
| Principal place of business | Houston, TX |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | 2021 |
| Revenue range | Decline to Disclose |
| SEC CIK | 1958777 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Pete O'Heeron | Executive Officer, DirectorChief Executive Officer | None linked |
| Richard C. Cilento | Director | None linked |
| Robert Hoffman | Director | None linked |
| Victoria Niklas | Director | None linked |
| Kathleen H. Rubins | Director | None linked |
| Leigh Steinberg | Director | None linked |
| Jason D. Davis | Executive OfficerChief Financial Officer | None linked |
| Ruben A. Garcia | Executive OfficerGeneral Counsel | None linked |
| Hamid Khoja | Executive OfficerChief Scientific Officer | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Sep 16, 2026 | D (original) | $500,001 | $500,001 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through September 29, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "FibroBiologics: SEC Form D deal record", https://vcbeast.com/deals/fibrobiologics-form-d-2026-09-15. Source: SEC EDGAR, accession 0001493152-26-042792.